Morgan Stanley has revised the price targets of a number of medical technology firms in a Tuesday note.

RxSight (RXST) has observed a challenging spending environment for its target demographic of adults in the 65-75 age range, Morgan Stanley analysts said, adding that patients are deferring procedures and opting for lower-cost alternatives such as monofocal intraocular lenses. Competitive pressures and new product launches in the space may impact the company's growth profiles in the longer term, they said.

The brokerage maintained RxSight's stock rating at overweight and cut the price target to $20 from $42.

Treace Medical Concepts' (TMCI) Q2 commentary implies a reduction of $2 million to $3 million on Street estimates, with the suggestion that patients had deferred some foot and ankle procedures in select cases, the analysts said. The company's guidance also gave off a "wait and see" dynamic, they said.

The brokerage maintained Treace's stock rating at equal-weight and reduced the price target to $8 from $10.

Insulet (PODD) continues to penetrate the insulin-intensive diabetes population with its ease of use, form, and accessibility with its Omnipod 5, the analysts said. The path to over $2.5 billion in revenue and double-digit growth is clear, they said.

The brokerage maintained Insulet's stock rating at overweight and increased the price target to $355 from $325.

Morgan Stanley also reduced the price target of Embecta (EMBC) to $15 from $20, Globus Medical (GMED) to $75 from $100, and Integra LifeSciences (IART) to $10 from $20. The brokerage also increased the price target of Transmedics (TMDX) to $103 from $80.

Price: 13.38, Change: -0.37, Percent Change: -2.68